Anzeige
Meldung des Tages: Durchbruch bei Drohnen-Batterien: Diese Nachricht schockt den Markt

Karyopharm Therapeutics Aktie News

Aktie
WKN:  A40YLC ISIN:  US48576U2050 US-Symbol:  KPTI Branche:  Biotechnologie Land:  USA
6,53 $
-0,1 $
-1,51%
5,5103 € 30.01.26
Depot/Watchlist
Marktkapitalisierung *
3,52 Mio. €
Streubesitz
60,73%
KGV
-0,61
Index-Zuordnung
-

Karyopharm Therapeutics News

12.05.25 - PR Newswire
Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification
Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume ...
08.05.25 - PR Newswire
Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025
Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025 PR Newswire
01.05.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
01.04.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
03.03.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
24.02.25 - PR Newswire
Karyopharm Announces 1-for-15 Reverse Stock Split
Karyopharm Announces 1-for-15 Reverse Stock Split PR Newswire
19.02.25 - PR Newswire
Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress
Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress PR ...
12.02.25 - PR Newswire
Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025 PR Newswire
03.02.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
26.01.25 - Börse-Global
Karyopharm Therapeutics Aktie: Visionäre Ausblicke realisiert
Die Karyopharm Therapeutics Aktie verzeichnete am 24. Januar 2025 einen bedeutenden Aufschwung mit einem Tagesplus von 3,27 Prozent. Der aktuelle Kurs liegt bei 0,66 EUR, ...
25.01.25 - Börse-Global
Karyopharm Therapeutics Aktie: Positives Momentum erzeugt!
Die Biotechnologie-​Aktie Karyopharm Therapeutics zeigt sich zum Ende Januar 2025 in einer dynamischen Phase. Am 24. Januar verzeichnete das Papier einen deutlichen ...
13.01.25 - PR Newswire
Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives
Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives PR Newswire
02.01.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
02.01.25 - PR Newswire
Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer
Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer PR Newswire
21.12.24 - Boersia.de
Karyopharm Therapeutics Aktie: Der Weg zur Lösung bleibt unklar …
Die Karyopharm Therapeutics Aktie zeigt zum Jahresende 2024 eine herausfordernde Entwicklung. Der Biotechnologie-​Konzern verzeichnet mit einem aktuellen Kurs von 0,62 EUR ...
09.12.24 - PR Newswire
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications PR Newswire
03.12.24 - PR Newswire
Karyopharm Therapeutics Provides Endometrial Cancer Program Update
Karyopharm Therapeutics Provides Endometrial Cancer Program Update PR Newswire
02.12.24 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
30.11.24 - Börse-Global
Karyopharm Therapeutics Aktie: Welche Optionen bestehen?
Die Karyopharm Therapeutics steht vor bedeutenden Terminen in der kommenden Woche. Das Biotechnologie-​Unternehmen wird am 3. Dezember an der Piper Sandler ...
25.11.24 - PR Newswire
Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference PR Newswire

Newssuche

Videos

newspaper
29.01.26 -10,12%
Rekordjagd bei Gold! Februar Ausblick & Forecast
Ab 2.2. (Montag) börsentäglich um 18 Uhr FEIERABEND-​TRADING. Echte Trades, strategiebasiert, ... Mehr »
Anzeige

Aktie im Fokus

Durchbruch bei Drohnen-Batterien
NEO Battery Materials Ltd
0,39 €
-3,94%
NEO Battery Materials Ltd Chart
Diese Nachricht schockt den Markt
Mehr zur Aktie »